SYH 2085
Alternative Names: SYH-2085Latest Information Update: 24 Mar 2026
At a glance
- Originator CSPC Pharmaceutical Group
- Class Antivirals; Small molecules
- Mechanism of Action Endonuclease inhibitors; Virus replication inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Influenza A virus infections; Influenza B virus infections
Most Recent Events
- 12 Jan 2026 Phase-I clinical trials in Influenza A virus infections (In volunteers) in China (PO) (NCT07412353)
- 12 Jan 2026 Phase-I clinical trials in Influenza B virus infections (In volunteers) in China (PO) (NCT07412353)
- 19 Dec 2025 Preclinical trials in Influenza A virus infections in China (PO) prior to December 2025